Unknown

Dataset Information

Side effects of standard adjuvant and neoadjuvant chemotherapy regimens according to age groups in primary breast cancer.


ABSTRACT:

Background

Elderly breast cancer patients are underrepresented in clinical trials and this leads to a lack of knowledge regarding the tolerance and side effects of modern chemotherapy regimens, especially in dose-dense (dd) or dose-intensified combination.

Patients and methods

In this analysis, data from 4 German, randomized (neo-)adjuvant trials, including anthracycline-based chemotherapy, were evaluated for toxicity, compliance and feasibility. Patients were grouped according to age.

Results

Of the 4,775 patients, 73.6% were < 60 years, 15.8% were 60-64 years and 10.6% were > 64 years. The patients' compliance decreased with increasing age, the rate of therapy discontinuations was 10.3%; 16.0% were > 64 years old (p < 0.001). The rate of dose reductions also increas

SUBMITTER: Reinisch M 

PROVIDER: S-EPMC3971817 | biostudies-literature | 2013 Mar

REPOSITORIES: biostudies-literature